Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2025-12-25 @ 8:43 PM
Study NCT ID:
NCT05571969
Status:
SUSPENDED
Last Update Posted:
2025-05-07
First Post:
2022-10-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Sponsor:
Allarity Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-05
First Submit QC Date:
None
Study First Post Date:
2022-10-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-05
Last Update Post Date:
2025-05-07
Last Update Post Date Type:
ACTUAL